XML 36 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)
12 Months Ended
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
shares
Number of Research Organizations 2  
Number of Operating Segments 1  
Revenue from Contract with Customer, Excluding Assessed Tax, Total $ 1,601,921 $ 1,681,076
Accounts Receivable, Allowance for Credit Loss, Ending Balance $ 0 $ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares 4,638,390 3,860,390
Alphazyme [Member]    
Equity Securities without Readily Determinable Fair Value, Amount $ 284,709  
Customer Concentration Risk [Member] | Revenue Benchmark [Member]    
Concentration Risk, Number of Customers 14 10
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Non-US [Member]    
Concentration Risk, Number of Customers 7 4
Concentration Risk, Percentage 49.70% 71.50%
Revenue from Contract with Customer, Excluding Assessed Tax, Total $ 796,000 $ 1,202,000
Customer Concentration Risk [Member] | Accounts Receivable [Member]    
Concentration Risk, Number of Customers 9 5
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Non-US [Member]    
Concentration Risk, Percentage 41.60% 69.50%
Revenue from Contract with Customer, Excluding Assessed Tax, Total $ 123,000 $ 388,000
Customer Concentration Risk [Member] | Contract Research Organizations [Member]    
Concentration Risk, Percentage 91.60% 86.60%
Customer Concentration Risk [Member] | Accounts Payable [Member] | Contract Research Organizations [Member]    
Concentration Risk, Percentage 68.10% 74.90%
Accounts Payable, Total $ 690,000 $ 706,000